The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.